Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Bicycle Therapeutics (BCYC) Research & Development (2018 - 2025)

Historic Research & Development for Bicycle Therapeutics (BCYC) over the last 8 years, with Q3 2025 value amounting to $58.4 million.

  • Bicycle Therapeutics' Research & Development rose 2105.25% to $58.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $238.3 million, marking a year-over-year increase of 4193.7%. This contributed to the annual value of $173.0 million for FY2024, which is 1052.42% up from last year.
  • Per Bicycle Therapeutics' latest filing, its Research & Development stood at $58.4 million for Q3 2025, which was up 2105.25% from $71.0 million recorded in Q2 2025.
  • Bicycle Therapeutics' 5-year Research & Development high stood at $71.0 million for Q2 2025, and its period low was $9.7 million during Q1 2021.
  • Moreover, its 5-year median value for Research & Development was $34.9 million (2024), whereas its average is $33.9 million.
  • Per our database at Business Quant, Bicycle Therapeutics' Research & Development surged by 12550.41% in 2023 and then soared by 85.35% in 2024.
  • Bicycle Therapeutics' Research & Development (Quarter) stood at $13.0 million in 2021, then soared by 90.79% to $24.7 million in 2022, then skyrocketed by 80.82% to $44.7 million in 2023, then increased by 11.37% to $49.8 million in 2024, then increased by 17.37% to $58.4 million in 2025.
  • Its last three reported values are $58.4 million in Q3 2025, $71.0 million for Q2 2025, and $59.1 million during Q1 2025.